Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|S-49076||S49076||Aurkb Inhibitors 20 AXL Inhibitor 28 FGFR1 Inhibitor 25 FGFR2 Inhibitor 19 FGFR3 Inhibitor 14 MET Inhibitor 56||S-49076 is a multi-kinase inhibitor that inhibits wild-type and mutant forms of MET and FGFR1-2, as well as FGFR3, AXL, MER, and AURKB, resulting in decreased downstream signaling, and potentially resulting in decreased tumor growth (PMID: 23804704, PMID: 28624695, PMID: 28619752).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR3 - TACC3||urinary bladder cancer||predicted - sensitive||S-49076||Preclinical||Actionable||In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 23804704, PMID: 23175443).||23175443 23804704|
|FGFR3 act mut||urinary bladder cancer||predicted - sensitive||S-49076||Preclinical||Actionable||In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells over expressing constitutively active FGFR3 in culture (PMID: 23804704).||23804704|
|FGFR2 act mut||stomach carcinoma||sensitive||S-49076||Preclinical - Cell line xenograft||Actionable||In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring FGFR2 activating mutations in culture and in cell line xenograft models (PMID: 23804704).||23804704|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|